Perhaps with the advent of easy administration and increased efficacy (as expected with Afrezza), the notion of insulin dependence, and it's sorted complications, will take on a significantly dimished perception in the choice of drugs used to treat the disease. I think this is what Al is shooting for, and it may be that it beats everything except Metformin to the head of the line.